GLP1RA and the Risk for ER Visits and Hospitalization

What is it about?

Medications called GLP1RAs (glucagon-like peptide-1 receptor agonists) have shown benefits in people with diabetes. However, while some studies suggest that GLP1RAs might reduce hospital stays for heart problems, it is unclear if they also lower emergency department (ED) visits and overall hospitalizations. In this study, we looked at how GLP1RAs affect ED visits and hospitalizations in people with chronic kidney disease compared to another common diabetes medication, DPP-4 inhibitors. We analyzed data from Ontario, Canada, for adults with kidney disease who started taking either a GLP1RA or a DPP-4 inhibitor and we compared the rates of ER visits and hospital stays. We found that people taking GLP1RAs had fewer ER visits and hospitalizations than those on DPP-4 inhibitors. This research suggests that GLP1RAs could help reduce ER visits and hospital stays, which would lessen the demand on healthcare resources. Further studies are needed to confirm these findings in different patient groups.

Featured Image

Why is it important?

This study demonstrates that the class of medications called GLP1RA which are popularly known for causing weight loss may also reduce overall ER visits and hospitalizations in patients living with kidney disease.